For years, many supplement ingredients have entered the market through self-affirmed GRAS determinations, letting brands and their suppliers document safety internally without waiting on FDA sign-off. A proposal to end that pathway and require agency notification for every GRAS claim would change the calculus for anyone planning a new formulation, especially novel ingredients, botanicals, or delivery formats like functional patches.
The open question isn't just legal, it's operational. Does FDA have the staff and bandwidth to review a much larger volume of submissions without creating a backlog that stalls product launches industry-wide? Brand owners should treat that uncertainty as a planning variable, not background noise.
The practical response is to get ahead of it. Ingredient dossiers, safety data, and manufacturing records that are already organized and audit-ready will move faster whatever the final rule looks like. Brands working with manufacturers who maintain rigorous documentation and regulatory affairs support will be better positioned than those scrambling to assemble a safety file after the rule takes effect.